TAK241018C15000
- 0.05
- -0.06-54.55%
Takeda Pharmaceutical Newsroom
Takeda Pharmaceutical Buy Rating Justified by Strong Sales, Pipeline Advancements, and Reduced Risk
Analysts Conflicted on These Healthcare Names: CSL (OtherCMXHF), Pro Medicus Limited (OtherPMCUF) and Takeda Pharmaceutical Co (OtherTKPHF)
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,000 Yen From 4,800 Yen, Keeps at Buy
Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Co (OtherTKPHF), Cerus (CERS) and Ultragenyx Pharmaceutical (RARE)
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 4,800 Yen From 5,600 Yen, Keeps at Buy
Oppenheimer Cuts Ovid to Perform, Cites Uncertainty Over Lead Drug
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy
Takeda Pharmaceutical Company (TAK) Receives a Hold From J.P. Morgan
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,200 Yen From 5,300 Yen, Keeps at Buy
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,300 Yen From 5,100 Yen, Keeps at Buy
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,100 Yen From 5,000 Yen, Keeps at Buy
TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $20 From $30, Maintains Outperform Rating
TD Cowen Maintains Outperform on Takeda Pharmaceutical, Lowers Price Target to $20
TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $30 From $24, Keeps Outperform Rating
TD Cowen Maintains Outperform on Takeda Pharmaceutical, Raises Price Target to $30
B of A Securities Upgrades Takeda Pharmaceutical to Buy, Announces $20 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Intercept Pharma (ICPT) and Takeda Pharmaceutical Company (TAK)
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,000 Yen From 4,600 Yen, Keeps at Buy
J.P. Morgan Sticks to Their Hold Rating for Takeda Pharmaceutical Company (TAK)